These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32888218)

  • 21. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
    de Vries NL; van de Haar J; Veninga V; Chalabi M; Ijsselsteijn ME; van der Ploeg M; van den Bulk J; Ruano D; van den Berg JG; Haanen JB; Zeverijn LJ; Geurts BS; de Wit GF; Battaglia TW; Gelderblom H; Verheul HMW; Schumacher TN; Wessels LFA; Koning F; de Miranda NFCC; Voest EE
    Nature; 2023 Jan; 613(7945):743-750. PubMed ID: 36631610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. γδ T cells: Major advances in basic and clinical research in tumor immunotherapy.
    Zhao Y; Dong P; He W; Zhang J; Chen H
    Chin Med J (Engl); 2024 Jan; 137(1):21-33. PubMed ID: 37592858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates.
    Mizuta S; Tagod MSO; Iwasaki M; Nakamura Y; Senju H; Mukae H; Morita CT; Tanaka Y
    ChemMedChem; 2019 Feb; 14(4):462-468. PubMed ID: 30637982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer.
    Nada MH; Wang H; Hussein AJ; Tanaka Y; Morita CT
    Oncoimmunology; 2021; 10(1):1989789. PubMed ID: 34712512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A close look at current γδ T-cell immunotherapy.
    Ma L; Feng Y; Zhou Z
    Front Immunol; 2023; 14():1140623. PubMed ID: 37063836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
    Kobayashi H; Tanaka Y; Shimmura H; Minato N; Tanabe K
    Anticancer Res; 2010 Feb; 30(2):575-9. PubMed ID: 20332473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical platforms to study therapeutic efficacy of human γδ T cells.
    Ou L; Wang H; Huang H; Zhou Z; Lin Q; Guo Y; Mitchell T; Huang AC; Karakousis G; Schuchter L; Amaravadi R; Guo W; Salvino J; Herlyn M; Xu X
    Clin Transl Med; 2022 Jun; 12(6):e814. PubMed ID: 35731974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
    Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
    Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harnessing γδ T cells in anticancer immunotherapy.
    Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
    Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.
    Landmeier S; Altvater B; Pscherer S; Juergens H; Varnholt L; Hansmeier A; Bollard CM; Moosmann A; Bisping G; Rossig C
    J Immunother; 2009 Apr; 32(3):310-21. PubMed ID: 19242369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic avenues for γδ T cells in cancer.
    Costa GP; Mensurado S; Silva-Santos B
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.
    Paul S; Lal G
    Int J Cancer; 2016 Sep; 139(5):976-85. PubMed ID: 27012367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
    Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
    Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
    Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
    Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The capability of heterogeneous γδ T cells in cancer treatment.
    Yan W; Dunmall LSC; Lemoine NR; Wang Y; Wang Y; Wang P
    Front Immunol; 2023; 14():1285801. PubMed ID: 38077392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
    Wilhelm M; Kunzmann V; Eckstein S; Reimer P; Weissinger F; Ruediger T; Tony HP
    Blood; 2003 Jul; 102(1):200-6. PubMed ID: 12623838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy.
    Chabab G; Barjon C; Bonnefoy N; Lafont V
    Front Immunol; 2020; 11():2186. PubMed ID: 33042132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.